Advances in medical sciences最新文献

{"title":"Meconium ferritin amounts and birth size of neonates: a pilot study","authors":"Ewa Skarżyńska ,&nbsp;Artur Jakimiuk ,&nbsp;Tadeusz Issat ,&nbsp;Krzysztof Krasuski ,&nbsp;Barbara Lisowska-Myjak","doi":"10.1016/j.advms.2025.05.001","DOIUrl":"10.1016/j.advms.2025.05.001","url":null,"abstract":"<div><h3>Purpose</h3><div>Ferritin amounts that accumulate in the meconium may provide new postnatal insights into intrauterine iron homeostasis and neonatal preparedness for the postnatal period. The most dynamic increases in fetal iron stores and fetal growth occur during the third trimester.</div></div><div><h3>Materials and methods</h3><div>This study involved 122 neonates born between 36 and 41 weeks of gestation, with birth weights from 2650 ​g to 4960 ​g and birth lengths ranging from 50 ​cm to 60 ​cm. Ferritin amounts per gram of meconium were determined via ELISA in the first meconium passed after birth.</div></div><div><h3>Results</h3><div>A significant week-by-week increase in the birth weight and length (<em>p</em> ​&lt; ​0.05) was accompanied by decreasing meconium ferritin amounts (<em>p</em> ​= ​0.021) across the gestational age range of 36–41 weeks. There were negative correlations (p ​&lt; ​0.05) between the systematic decrease in meconium ferritin amounts and the gestational age across the same range (r ​= ​-0.18) and between ferritin amounts and the birth weight and length of newborns (r ​= ​-0.20 and r ​= ​-0.31). Neonates born at 36–37 weeks of gestation had lower birth weight and length, while their meconium ferritin amounts were nearly twice as high as in neonates born at 38–39 weeks or 40–41 weeks (<em>p</em> ​&lt; ​0.05).</div></div><div><h3>Conclusions</h3><div>Systematic decreases in meconium ferritin amounts from 36 to 41 weeks of gestation may suggest a gradual and gestational age-appropriate maturation of the mechanisms responsible for adaptation of the fetus to postnatal life. Determining a cut-off value for meconium ferritin amounts could aid in optimal management of newborns after birth.</div></div>","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":"70 2","pages":"Pages 237-242"},"PeriodicalIF":2.5,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143956243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Systemic Immune-Inflammation Index with in-hospital mortality of cardiogenic shock patients supported with extracorporeal membrane oxygenation.","authors":"Shixing Li, Hao Wang, Jin Yu, Jingsong Xu, Yan Xu","doi":"10.1016/j.advms.2025.04.002","DOIUrl":"https://doi.org/10.1016/j.advms.2025.04.002","url":null,"abstract":"<p><strong>Purpose: </strong>The systemic immune-inflammation index (SII) is a useful predictor in cardiovascular diseases. The purpose of this study was to investigate the association of SII with in-hospital mortality in patients with cardiogenic shock (CS) supported with extracorporeal membrane oxygenation (ECMO).</p><p><strong>Patients and methods: </strong>A total of 126 CS patients received ECMO implantation between January 2020 and December 2023. SII was calculated as follows: SII = neutrophil count × platelet count / lymphocyte count at admission. Participants were divided into high or low SII group based on the cut-off value of SII. In-hospital mortality was compared between the groups.</p><p><strong>Results: </strong>The optimal SII cut-off value for predicting in-hospital mortality in CS patients supported with ECMO was 1735.9 (AUC 0.68, p = 0.001). In-hospital mortality was significantly higher in the high SII group compared to the low SII group (59.09% vs. 21.67%, p <0.001). The univariate and multivariate logistic regression analyses had shown that SII and left ventricular ejection fraction (LVEF) were identified as independent predictors of in-hospital mortality in CS patients supported with ECMO (OR: 1.001, 95% CI: 1.000-1.002, p = 0.007 and OR: 0.881, 95% CI: 0.803-0.966, p = 0.007, respectively). SII combined with LVEF offered a superior prognostic capability compared to SII alone (AUC 0.707, v.s. AUC 0.68).</p><p><strong>Conclusion: </strong>We demonstrated that elevated admission SII was independently associated with in-hospital mortality in CS patients supported with ECMO. These findings highlight the potential role of SII as an indicator of mortality risk in this population.</p>","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Collagen (rs3134646) and ARHGAP15 (rs4662344) genetic variants may predispose to colonic diverticulosis","authors":"Piotr Nehring ,&nbsp;Grzegorz Placha ,&nbsp;Adam Przybyłkowski","doi":"10.1016/j.advms.2025.04.001","DOIUrl":"10.1016/j.advms.2025.04.001","url":null,"abstract":"<div><h3>Purpose</h3><div>Colonic diverticulosis is a common condition in older adults in the entire world. Besides environmental factors, there are emerging data on underlying genetic predisposition to diverticula formation. The study aimed to identify genetic factors associated with colonic diverticulosis.</div></div><div><h3>Patients and methods</h3><div>The study involved 323 patients, 134 with colonic diverticulosis, and 189 healthy controls. In all study participants the following genetic variants were assessed using RT-PCR: rs1800587 in <em>IL1</em>, rs16944, and rs2853550 in <em>IL1B</em>, rs3134646, and rs6434304 in <em>COL3A1</em>, rs3771810, and rs3771863 in <em>TACR1</em>, rs4644560 in <em>NK2R</em>, rs4662344 in <em>ARHGAP15</em>, rs67153654 in <em>FAM155A</em>, and rs7848647 in <em>TNFSF15</em>.</div></div><div><h3>Results</h3><div>Both, the allele C of the <em>COL3A1</em> (rs3134646) variant and allele T of the <em>ARHGAP15</em> (rs4662344) variant, were shown to be associated with diverticulosis, compared to healthy controls in co-dominant and recessive models. Both of them were more frequently reported in patients with colonic diverticulosis, compared to healthy controls.</div><div>There were no allelic or genetic associations in patients with diverticulosis or diverticulitis compared to healthy controls, for the following genetic variants: <em>IL1A</em> (rs1800587), <em>IL1B</em> (rs16944, rs2853550), <em>COL3A1</em> (rs6434304), <em>TACR1</em> (rs3771810, rs3771863), <em>NK2R</em> (rs4644560), <em>FAM155A</em> (rs67153654) and <em>TNFSF15</em> (rs7848647).</div></div><div><h3>Conclusions</h3><div>The allele C of <em>COL3A1</em> (rs3134646) and allele T of the <em>ARHGAP15</em> (rs4662344) may predispose to colonic diverticulosis. When viewed in the context of previous studies, these findings suggest that the development of colonic diverticula may be influenced by the involvement and degradation of the extracellular matrix.</div></div>","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":"70 2","pages":"Pages 231-236"},"PeriodicalIF":2.5,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143907093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of salusin-β in paediatric patients with chronic kidney disease or hypertension","authors":"Mirjam Močnik ,&nbsp;Sonja Golob Jančič ,&nbsp;Martina Filipič ,&nbsp;Evgenija Homšak ,&nbsp;Mateja Svetej ,&nbsp;Nataša Marčun Varda","doi":"10.1016/j.advms.2025.02.006","DOIUrl":"10.1016/j.advms.2025.02.006","url":null,"abstract":"<div><h3>Purpose</h3><div>Salusins are newly identified endogenous peptides implicated in the atherosclerotic process. Salusin-β, in particular, is recognized for its proatherogenic role. Given that atherosclerosis can commence in childhood, salusin-β holds promise as a potential biomarker for cardiovascular risk assessment. The objective of our study was to investigate salusin-β levels in children with early stages of chronic kidney disease (CKD) or hypertension (HTN), and compare them to healthy controls. Furthermore, we aimed to evaluate its association with obesity and pulse wave velocity (PWV), the latter being a well-established marker for determining arterial elasticity.</div></div><div><h3>Materials and methods</h3><div>This cross-sectional study involved 96 paediatric patients, including 46 with CKD and 50 with HTN, as well as 33 healthy controls. Anthropometric measurements, PWV assessments, serum salusin-β values, and basic laboratory investigations were conducted for all participants.</div></div><div><h3>Results</h3><div>Salusin-β levels were found to be elevated in patients with CKD (<em>p</em> ​= ​0.014), but not in patients with HTN when compared to healthy controls. When correlating salusin-β levels with PWV, a significant but weak correlation was observed (r ​= ​0.211, <em>p</em> ​= ​0.020).</div></div><div><h3>Conclusions</h3><div>Salusin-β levels were elevated in paediatric patients with CKD. Additionally, salusin-β levels correlated significantly with PWV. Obesity played a smaller role in these correlations, with significant correlations observed only after combining cardiovascular risk factors revealing certain associations between salusin-β levels and some cardiovascular variables, but with inconclusive findings and, in some instances, even contrary to anticipated outcomes.</div></div>","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":"70 1","pages":"Pages 184-190"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143527227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of patients with severe asthma reported to be eligible or non-eligible for biologic therapy in Poland: Results from the international observational study RECOGNISE","authors":"Robert M. Mróz ,&nbsp;Łukasz Minarowski ,&nbsp;Jolanta Biegalska","doi":"10.1016/j.advms.2025.03.003","DOIUrl":"10.1016/j.advms.2025.03.003","url":null,"abstract":"<div><h3>Purpose</h3><div>To analyze characteristics of real-world patients with severe asthma in Poland and identify factors determining clinicians’ opinion on the eligibility for biologics.</div></div><div><h3>Methods</h3><div>In this retrospective, multi-national, single-visit study (NCT03629782), investigators were asked whether the patient might benefit from a referral for further clinical assessment and potentially biologic therapy. Asthma exacerbations and healthcare resource utilization (HCRU) in the last 12 months were documented by the investigators. Patient-reported outcomes included St George's Respiratory Questionnaire (SGRQ) and Asthma Control Questionnaire (ACQ-6).</div></div><div><h3>Results</h3><div>Of 1025 patients, 146 were enrolled in Poland. Investigators considered 77.4 ​% of patients eligible for biologics and 22.6 ​% non-eligible. Patients considered eligible were diagnosed at younger age than non-eligible (median 39 vs 45 years; p ​= ​0.0113) and more frequently had a history of atopy (46 ​% vs 21.2 ​%; p ​= ​0.0106). Eligible patients had a higher frequency (93.8 ​% vs 66.7 ​%, p ​&lt; ​0.0001) and number of exacerbations (median 2 vs 1, p ​= ​0.0003). Among eligible patients, 81.4 ​% and among non-eligible, 66.7 ​% had not well-controlled asthma; long-term oral corticosteroids were used by 46.0 ​% and 51.5 ​%, respectively. Short-term corticosteroid use was more frequent in biologics-eligible than in non-eligible patients (82.3 ​% vs 48.5 ​%, p ​&lt; ​0.0001). Patients eligible for biologics had a higher median SGRQ total score (64.7 vs 48.4; p ​= ​0.0075) and HRCU (63.7 ​% vs 9.1 ​%; p ​&lt; ​0.0001).</div></div><div><h3>Conclusions</h3><div>In Poland, 3 in 4 patients with severe asthma are recognized by clinicians as potential candidates for biologics. However, eligibility is not associated with long-term oral corticosteroid use, highlighting the need to better inform the physicians about the benefits of biologic therapy.</div></div>","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":"70 1","pages":"Pages 203-208"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143661896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Column chart prediction model for ovarian cancer based on serum ovarian tumor related biomarkers and validation","authors":"Yuting Song ,&nbsp;Libo Liu ,&nbsp;Jie Gao ,&nbsp;Naibao Wu ,&nbsp;Jiwei Yin","doi":"10.1016/j.advms.2025.03.001","DOIUrl":"10.1016/j.advms.2025.03.001","url":null,"abstract":"<div><h3>Purpose</h3><div>The aim was to study the predictive model and validate serum ovarian tumor-related biomarkers for ovarian cancer histograms.</div></div><div><h3>Method</h3><div>We randomly selected 181 patients with ovarian tumors and 80 healthy individuals who underwent physical examinations from the hospital's medical record information system as the study participants. Clinical data and detection results of ovarian tumor-related markers such as serum carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), and human epididymal protein (HE4) were collected from all study participants for analysis.</div></div><div><h3>Result</h3><div>Significant differences were found in serum CEA, CA125, CA19-9, and HE4 levels between healthy controls, benign ovarian tumors, and ovarian cancer (<em>P</em> ​&lt; ​0.05). Dysmenorrhea (present), family history (present), age at menarche, menstrual period, number of pregnancies, natural abortion frequency, number of induced abortions, CEA, CA125, CA19-9, HE4 were all influencing factors for the incidence of ovarian cancer (<em>P</em> ​&lt; ​0.05). The number of induced abortions, CEA, CA125, CA19-9, and HE4 were all independent risk factors for ovarian cancer, while the natural abortion frequency was a protective factor for ovarian cancer (<em>P</em> ​&lt; ​0.05). The constructed column chart prediction model had good discrimination and prediction accuracy for ovarian cancer, good clinical utility, and higher predictive performance for ovarian cancer than traditional ROMA models.</div></div><div><h3>Conclusion</h3><div>The ovarian cancer column chart prediction model based on serum ovarian tumor related markers has good discrimination and prediction accuracy for ovarian cancer, with high clinical utility. Future research may need to incorporate more serum markers related to ovarian cancer to further improve the performance of predictive models.</div></div>","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":"70 1","pages":"Pages 209-218"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conduction system optimized cardiac resynchronization therapy– exceptional modality of cardiac pacing in patients with severe heart failure. A hope for non-responders?","authors":"Jędrzej Michalik ,&nbsp;Maciej Sterliński ,&nbsp;Ewa Świerżyńska-Wodarska ,&nbsp;Aleksandra Klaus ,&nbsp;Marek Szołkiewicz","doi":"10.1016/j.advms.2025.02.008","DOIUrl":"10.1016/j.advms.2025.02.008","url":null,"abstract":"<div><div>For many years, the apex of the right ventricle (RV) seemed to be a sufficiently good site for ventricular pacing, effectively protecting both the health and life of patients with atrioventricular conduction disorders. However, the studies have demonstrated that this is not an optimal site, since it leads to electrical and mechanical interventricular asynchrony, which in some cases (15–20 ​%) results in the development of pacing-induced cardiomyopathy (PICM). The introduction of biventricular cardiac resynchronization therapy (BiV-CRT) into clinical practice was a real breakthrough in the development of modern electrotherapy, and conduction system pacing (CSP) has heralded even greater hopes. The CSP-optimized CRT is the most complex modality of CRT, involving the simultaneous pacing of His bundle or its left branch, and additionally, epicardial pacing of the left ventricle. This modality of pacing may represent the most optimal method for spreading the ventricle depolarization wave in severely damaged cardiac muscle and may represent a real hope for patients who do not adequately respond to other forms of CRT.</div></div>","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":"70 1","pages":"Pages 197-202"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determinants and dynamics of the seroprevalence of anti-SARS-CoV-2 antibodies in Poland","authors":"Justyna Adamczuk ,&nbsp;Karol Adam Kamiński ,&nbsp;Sebastian Sołomacha ,&nbsp;Małgorzata Kazberuk ,&nbsp;Magdalena Chlabicz ,&nbsp;Piotr Czupryna ,&nbsp;Justyna Dunaj-Małyszko ,&nbsp;Anna Citko ,&nbsp;Paweł Sowa ,&nbsp;Marlena Dubatówka ,&nbsp;Magda Łapińska ,&nbsp;Łukasz Kiszkiel ,&nbsp;Łukasz Szczerbiński ,&nbsp;Piotr Paweł Laskowski ,&nbsp;Maciej Alimowski ,&nbsp;Anna Moniuszko-Malinowska","doi":"10.1016/j.advms.2025.03.002","DOIUrl":"10.1016/j.advms.2025.03.002","url":null,"abstract":"<div><h3>Purpose</h3><div>In the present study, we aimed to assess the anti-SARS-CoV-2 antibodies in population and in convalescents 6 months after infection with COVID-19.</div></div><div><h3>Patients and methods</h3><div>The study population consisted of 2 groups, i.e. group I: 232 post-COVID-19 patients, and group II: 544 patients from a population cohort.</div><div>Detection of anti-N antibodies was performed with Elecsys Anti-SARS-CoV-2 and anti-S antibodies with LIAISON SARS-CoV-2 S1/S2 IgG tests.</div></div><div><h3>Results</h3><div>After the Omicron wave, gradual increase in the prevalence of the analyzed antibodies was observed in the general population - up to 92.5 ​% of anti-S and 69.7 ​% of anti-N antibodies. In the COVID-19 convalescents, 6 months after infection, 4.3 ​% and 3.7 ​% did not generate significant titers of anti-S and anti-N antibodies, respectively. Among patients, who were vaccinated, 1 ​% did not generate anti-S antibodies. The median age of non-responders was higher than that of responders. Sex did not influence the results. Comparison of anti-N and anti-S antibodies 6 months after infection in the whole group showed higher anti-N titer in patients who suffered from the disease than in the general population. In the general population, 17.4 ​% of participants had anti-N antibodies, and 9 ​% had anti-S antibodies, despite no prior vaccination or history of COVID-19.</div></div><div><h3>Conclusions</h3><div>High prevalence of anti-N antibodies in patients reporting no history of COVID-19 during last wave, even after official end of the pandemic suggests high prevalence of SARS-CoV-2 in the environment and frequent asymptomatic or unspecific COVID-19, what is of high importance from the public health perspective.</div></div>","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":"70 1","pages":"Pages 219-228"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Genome-engineering technologies for modeling and treatment of cystic fibrosis” [Adv Med Sci (2023 Sept) 68(1) 111–120]","authors":"Michał Dębczyński ,&nbsp;Damian Mojsak ,&nbsp;Łukasz Minarowski ,&nbsp;Monika Maciejewska ,&nbsp;Paweł Lisowski ,&nbsp;Robert M. Mróz","doi":"10.1016/j.advms.2025.01.009","DOIUrl":"10.1016/j.advms.2025.01.009","url":null,"abstract":"","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":"70 1","pages":"Page 229"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143424663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trimethylamine N-oxide as a potential prognostic biomarker for mortality in patients with COVID-19 disease","authors":"Zinnet Şevval Aksoyalp ,&nbsp;Betül Rabia Erdoğan ,&nbsp;Saliha Aksun ,&nbsp;Melih Kaan Sözmen ,&nbsp;Murat Aksun ,&nbsp;Cüneyt Kemal Buharalıoğlu ,&nbsp;Nagihan Altıncı-Karahan ,&nbsp;Nergiz Hacer Turgut ,&nbsp;Tijen Kaya-Temiz","doi":"10.1016/j.advms.2025.02.002","DOIUrl":"10.1016/j.advms.2025.02.002","url":null,"abstract":"<div><h3>Purpose</h3><div>Trimethylamine N-oxide (TMAO) is suggested as a biomarker for inflammatory and cardiovascular diseases which are identified as risk factors for severe cases of coronavirus disease 2019 (COVID-19). Our primary aim was to assess prognostic potential of serum TMAO levels in predicting COVID-19-related mortality. The secondary aim was to examine the potential of various biochemical parameters, particularly those associated with inflammation or thrombosis, as predictors of mortality.</div></div><div><h3>Patients and methods</h3><div>In this prospective and single-centre study, COVID-19 patients were categorized as death (group 1) or discharged (group 2) based on their in-hospital mortality status. The characteristics of participants were documented, and clinical data, including TMAO, angiotensin-converting enzyme-2 (ACE2), and neutrophil to lymphocyte ratio (NLR), were determined. The association of these independent variables with the COVID-19-related mortality, was assessed by calculation of crude odds ratios (OR) in bivariate and logistic regression analysis. Receiver operation characteristic (ROC) analysis was used for cut-off values.</div></div><div><h3>Results</h3><div>The serum levels of TMAO, ACE2 and NLR were markedly higher in group 1 on the days of hospital admission (<em>p</em> ​&lt; ​0.05, <em>p</em> ​&lt; ​0.05, and <em>p</em> ​&lt; ​0.01, respectively). Serum TMAO levels (OR 1.422; 95 ​% CI [1.067–1.894]; <em>p</em> ​= ​0.016) and NLR (OR 1.166; 95 ​% CI [1.012–1.343]; <em>p</em> ​= ​0.033) were determined as independent predictors for COVID-19-related mortality with after multivariate logistic regression analysis. The optimal cut-off values were detected as 7.9 ​ng/ml for TMAO (71 ​% sensitivity, 68 ​% specificity, AUC ​= ​0.701).</div></div><div><h3>Conclusions</h3><div>The findings of this initial study indicate that serum TMAO levels and NLR may be useful in predicting mortality in the early stages of COVID-19.</div></div>","PeriodicalId":7347,"journal":{"name":"Advances in medical sciences","volume":"70 1","pages":"Pages 174-183"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143373482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}